SecBot SecBot

PASG

Passage BIO, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001787297 Biotech & Drug Discovery
$4.13 −0.12 (−2.82%)
Nov 16 4:00 PM ET · prev $4.25
Market cap
$12.9M
Nano cap
Median target
$15.50
+275% · range $8.00–23.00
1 year
−54.0%
from $8.98 · Nov 17
30 days
+15.4%
from $3.58
52-week range
$3.32–19.85
−79% from high · low Nov 2
Avg volume 20D
15.5K
Oct 22 spike 43.9K
Short interest
49.6K
≈1.5% of shares · −28.1%
Days to cover
4.0
at average volume
Insider net
+$206.1K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 2 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 6/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $206.1K at an average $4.12. No open-market sales.

  • InstitutionsBEARISH

    Q3 2026: 0 added (0 new), 4 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$2.820 → −$3.750 over 90 days.

  • Short sellersCOVERING

    Short interest −28.1% to 49.6K shares. 4.0 days to cover, ≈1.5% of shares.

  • TrendUPTREND

    1% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCTRIM72,741$327.3K
UBS Group AGNEAR_EXIT417$1.9K
MORGAN STANLEYNEAR_EXIT362$1.6K
RENAISSANCE TECHNOLOGIES LLCTRIM47,892$233.7K
Erste Asset Management GmbHTRIM40,665$197.2K
UBS Group AGTRIM13,565$66.2K
GEODE CAPITAL MANAGEMENT, LLCADD41,380$324.9K
UBS Group AGDOUBLED27,501$215.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Apr 2026
12-month targets · 2 analysts

Price is below the lowest target. Median implies +275%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Apr 21, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Apr 21, 2026Chardan Capital
DOWNGRADE
DOWNGRADENeutral
Apr 21, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Apr 21, 2026Wedbush
DOWNGRADE
DOWNGRADENeutral
Mar 31, 2026Oppenheimer
INITIATE
INITIATEOutperform
Mar 4, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$206.1K
bought · 1 insider
$0
sold · 0 insiders
+0.3%
vs their $4.12 cost
DateInsiderTypeValue
Jun 25, 2026
Lynx1 Capital Management LP
10%+ Owner
Jun 25, 2026
BUY$206.1K
May 19, 2026
Countouriotis Athena
Director
May 19, 2026
AWARD10,539 sh
May 19, 2026
GOWEN MAXINE
Director
May 19, 2026
AWARD10,539 sh
May 19, 2026
Kapadia Sandip
Director
May 19, 2026
AWARD10,539 sh
May 19, 2026
Porter Derrell
Director
May 19, 2026
AWARD10,539 sh
May 19, 2026
Kassberg Thomas Richard
Director
May 19, 2026
AWARD10,539 sh
May 19, 2026
Sondhi Dolan
Director
May 19, 2026
AWARD10,539 sh
Mar 16, 2026
Chou William
PRESIDENT AND CEO
Mar 16, 2026
AWARD58,000 sh

Earnings setup

Estimates
−$3.75
EPS estimate, this quarter
−33%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.75-$3.75–-$3.75-33.0%$0.00
Next Q-$2.33-$4.06–-$1.01-20.8%$0.00
Current FY-$14.08-$14.08–-$14.08-24.2%$0.00
Next FY-$11.55-$11.55–-$11.55-11.2%$0.00

Short side

FINRA· Oct 30, 2026
49,551
shares short
-28.1%
vs prior settlement
4.0
days to cover
≈1.5%
of shares outstanding
Trading halts
Nov 6, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 Earnings calendar
PASG Q3 2026 Earnings Scheduled · 2026-11-09
Nov 6, 2026 SEC
Passage Bio stockholders approved all proposals related to the reverse merger with Remix Therapeutics, including share…
8-K · Impact 5/10
Oct 13, 2026 SEC
Passage BIO's registration statement on Form S-4 (File No. 333-297601) was declared effective by the SEC on October 9…
EFFECT · Impact 3/10
Oct 8, 2026 SEC
Passage Bio (PASG) filed Amendment No. 4 to its S-4 registration statement for the proposed reverse merger with Remix…
S-4/A · Impact 6/10
Sep 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC · TRIM
72,741 shares ($327.3K)
Sep 30, 2026 Inst.
UBS Group AG · NEAR_EXIT
417 shares ($1.9K)
Jun 25, 2026 Insider
Lynx1 Capital Management LP bought 50,055 shares
10%+ Owner @ $4.12 ($206.1K)
May 19, 2026 Insider
Countouriotis Athena was granted 10,539 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

13 filings · 2 press releases · 1 bullish · 6 bearish · 1 mixed · 5 neutral
All PASG filing & press-release reports (15)